Oxygenta Pharmaceutical Ltd
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
- Market Cap ₹ 170 Cr.
- Current Price ₹ 46.0
- High / Low ₹ 134 / 45.3
- Stock P/E
- Book Value ₹ -9.92
- Dividend Yield 0.00 %
- ROCE -24.9 %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 68.2 to 17.0 days.
- Company's median sales growth is 42.9% of last 10 years
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -2.02%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 | |
| 6 | 10 | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 130 | |
| Operating Profit | -3 | -4 | -4 | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -17 |
| OPM % | -142% | -67% | -34% | -59% | -31% | -10% | -57% | 7% | 2% | -23% | -24% | -9% | -15% |
| 0 | 0 | 0 | 1 | 1 | 0 | 4 | 2 | 1 | -1 | 0 | 1 | -0 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 |
| Depreciation | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 2 |
| Profit before tax | -4 | -7 | -6 | -6 | -4 | -3 | -6 | 3 | -0 | -11 | -14 | -12 | -25 |
| Tax % | 5% | -11% | 0% | 2% | 1% | -7% | -3% | 7% | 24% | 2% | -75% | -16% | |
| -4 | -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 | |
| EPS in Rs | -4.21 | -5.99 | -5.39 | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.62 | -4.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 51% |
| 3 Years: | 22% |
| TTM: | 60% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | 1% |
| 3 Years: | % |
| TTM: | -4700% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | % |
| 3 Years: | 10% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -19 | -26 | -32 | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -62 | -74 |
| 11 | 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 73 | |
| 17 | 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 81 | |
| Total Liabilities | 18 | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 117 |
| 16 | 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 40 | 41 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 44 | 75 | |
| Total Assets | 18 | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 117 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3 | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | |
| -2 | 1 | -2 | -1 | -0 | -1 | -0 | -7 | -5 | -10 | -4 | -11 | |
| 4 | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 9 | |
| Net Cash Flow | -1 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 |
| Free Cash Flow | -4 | -7 | -1 | -0 | 1 | -8 | -3 | -8 | -7 | -11 | -17 | -9 |
| CFO/OP | 78% | 104% | -20% | -13% | -33% | 396% | 35% | -37% | -106% | 23% | 135% | -28% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 128 | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 |
| Inventory Days | 33 | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 |
| Days Payable | 10,165 | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 |
| Cash Conversion Cycle | -10,004 | -1,678 | -582 | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 |
| Working Capital Days | -1,576 | -616 | -454 | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 |
| ROCE % | -188% | -1% | -47% | -42% | -25% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Coal Consumption MT |
|
||||||||||
| Number of Permanent Employees Count |
|||||||||||
| Power and Fuel Consumption Lakh Units |
|||||||||||
| Installed Capacity (Bulk Drugs) MTPA |
|||||||||||
Documents
Announcements
-
Closure of Trading Window
25 Mar - Trading window closed from 01.04.2026 until 48 hours after audited FY2025-26 results; board meeting to approve results and declare them if approved, notice to follow.
-
Announcement Under Regulation 30 Of SEBI (LODR), Regulations, 2015.
20 Feb - Order set aside ₹41,31,351 tax demand for 2017-18; received 19 Feb 2026.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 14 Feb
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
13 Feb - Virupaksha bought 2,23,632 Oxygenta shares (0.60%) on 13-02-2026; promoter holding now 56.50%.
-
Un-Audited Results For The Quarter And Nine Months Ended 31.12.2025.
4 Feb - Board approved unaudited Q3/9M (ended 31‑Dec‑2025) results; limited review; POSH ICC reconstituted effective 04‑Feb‑2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products:[1]
Losartan potassium intermediate, Gabapentin intermediate, Antihypertensive drugs, Anti
cancer drugs, Antiulcer drugs, Antiretroviral drugs, Antihypertensive drugs, Antiviral drugs.